Gena Wang
Stock Analyst at Barclays
(3.34)
# 994
Out of 5,041 analysts
223
Total ratings
45.21%
Success rate
4.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLLS Cellectis | Maintains: Overweight | $4 → $8 | $3.48 | +129.89% | 5 | Oct 17, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $82 | $57.83 | +41.79% | 4 | Oct 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Equal-Weight | $7 → $17 | $18.69 | -9.04% | 10 | Sep 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $78 → $80 | $70.86 | +12.90% | 13 | Sep 23, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $50 → $37 | $13.03 | +183.96% | 7 | Aug 8, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $59 → $62 | $49.15 | +26.14% | 4 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $42 → $56 | $67.61 | -17.17% | 17 | Aug 6, 2025 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $25 → $21 | $27.96 | -24.89% | 10 | Aug 6, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $40 → $31 | $26.74 | +15.93% | 10 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $329 → $460 | $463.43 | -0.74% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $10 → $22 | $22.81 | -3.55% | 15 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $46 | $66.40 | -30.72% | 16 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $5.62 | +77.94% | 7 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $5 | $0.63 | +689.52% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $38 | $11.34 | +235.10% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $7.20 | +52.78% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.98 | +418.39% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $25.60 | +1.56% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $421.39 | +10.82% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $3.72 | -19.35% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $54.48 | +57.86% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $33.53 | +141.57% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $31.86 | +195.04% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $17.74 | -49.27% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $11.22 | +122.82% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.72 | +106.42% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $5.23 | +72.08% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.48 | +4,918.25% | 1 | Jan 6, 2017 |
Cellectis
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.48
Upside: +129.89%
Cytokinetics
Oct 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $57.83
Upside: +41.79%
Kodiak Sciences
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $18.69
Upside: -9.04%
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Overweight
Price Target: $78 → $80
Current: $70.86
Upside: +12.90%
REGENXBIO
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $13.03
Upside: +183.96%
Avidity Biosciences
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $49.15
Upside: +26.14%
CRISPR Therapeutics AG
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $67.61
Upside: -17.17%
Beam Therapeutics
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $27.96
Upside: -24.89%
Moderna
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $40 → $31
Current: $26.74
Upside: +15.93%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $329 → $460
Current: $463.43
Upside: -0.74%
Jul 30, 2025
Upgrades: Equal-Weight
Price Target: $10 → $22
Current: $22.81
Upside: -3.55%
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $42 → $46
Current: $66.40
Upside: -30.72%
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $5.62
Upside: +77.94%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.63
Upside: +689.52%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $11.34
Upside: +235.10%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $7.20
Upside: +52.78%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.98
Upside: +418.39%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $25.60
Upside: +1.56%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $421.39
Upside: +10.82%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $3.72
Upside: -19.35%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $54.48
Upside: +57.86%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $33.53
Upside: +141.57%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $31.86
Upside: +195.04%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $17.74
Upside: -49.27%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $11.22
Upside: +122.82%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.72
Upside: +106.42%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $5.23
Upside: +72.08%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.48
Upside: +4,918.25%